Patent waiver not enough for vax rollout, expand production: WTO chief

Ngozi Okonjo-Iweala has argued in favour of expanding Covid-19 vaccine production and ending export restrictions, saying that getting a patent waiver would not be enough

Ngozi Okonjo
World Trade Organization (WTO) Director-General Ngozi Okonjo-Iweala
IANS Brussels
2 min read Last Updated : May 21 2021 | 8:43 AM IST

World Trade Organization (WTO) Director-General Ngozi Okonjo-Iweala has argued in favour of expanding Covid-19 vaccine production and ending export restrictions, saying that getting a patent waiver would not be enough.

She said this when answering a question on what measures are needed to accelerate equitable access to vaccines during a meeting of the European Parliament's Committee on Trade, Xinhua reported.

"Getting the Intellectual Property (IP) rights waiver for vaccines will not be enough," she said on Thursday.

Okonjo-Iweala listed three other routes, namely, reducing export restrictions and reinforcing supply chains for vaccines, working with manufacturers to expand production, and transferring the necessary technology and expertise to produce the complicated vaccines.

"The IP waiver is a hot issue on which I cannot take sides. But we need more flexibility and automatic access for developing countries, and at the same time we have to protect research and development," added the WTO chief.

The Trade Committee is set to discuss calls for patent waivers for Covid-19 vaccines on May 25.

No consensus was reached among the members of the European Parliament (MEPs) on Wednesday regarding a proposal for a temporary waiver of patent rights for Covid-19 vaccines in a bid to speed up the global vaccine rollout.

A resolution will be put to a vote at the European Parliament's plenary session in June. Any decision on waiving IP rights will be taken by the WTO.

--IANS

int/pgh

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineWTO

First Published: May 21 2021 | 8:23 AM IST

Next Story